[go: up one dir, main page]

WO2008016995A3 - Methods of identifying modulators of insulin signalling - Google Patents

Methods of identifying modulators of insulin signalling Download PDF

Info

Publication number
WO2008016995A3
WO2008016995A3 PCT/US2007/075001 US2007075001W WO2008016995A3 WO 2008016995 A3 WO2008016995 A3 WO 2008016995A3 US 2007075001 W US2007075001 W US 2007075001W WO 2008016995 A3 WO2008016995 A3 WO 2008016995A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
identifying modulators
insulin signalling
insulin
signalling
Prior art date
Application number
PCT/US2007/075001
Other languages
French (fr)
Other versions
WO2008016995A2 (en
Inventor
Cullen Taniguchi
Koji Ueki
C Ronald Kahn
Original Assignee
Joslin Diabetes Center Inc
Cullen Taniguchi
Koji Ueki
C Ronald Kahn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc, Cullen Taniguchi, Koji Ueki, C Ronald Kahn filed Critical Joslin Diabetes Center Inc
Publication of WO2008016995A2 publication Critical patent/WO2008016995A2/en
Publication of WO2008016995A3 publication Critical patent/WO2008016995A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates to methods of identifying drugs for the treatment of insulin resistance and diabetes.
PCT/US2007/075001 2006-08-01 2007-08-01 Methods of identifying modulators of insulin signalling WO2008016995A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82111806P 2006-08-01 2006-08-01
US60/821,118 2006-08-01

Publications (2)

Publication Number Publication Date
WO2008016995A2 WO2008016995A2 (en) 2008-02-07
WO2008016995A3 true WO2008016995A3 (en) 2008-11-27

Family

ID=38997846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075001 WO2008016995A2 (en) 2006-08-01 2007-08-01 Methods of identifying modulators of insulin signalling

Country Status (1)

Country Link
WO (1) WO2008016995A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085396A1 (en) * 2001-04-24 2002-10-31 President And Fellows Of Harvard College Inhibition of jun kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085396A1 (en) * 2001-04-24 2002-10-31 President And Fellows Of Harvard College Inhibition of jun kinase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
TANIGUCHI C.M. ET AL.: "Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN", PROC. NATL. ACAD. SCI. USA, vol. 103, no. 32, July 2006 (2006-07-01), pages 12093 - 12097 *
THIRONE A.C.P. ET AL.: "Opposite Effect of JAK2 on Insulin-Dependent Activation of Mitogen-Activated Protein Kinases and Akt in Muscle Cells", DIABETES, vol. 55, April 2006 (2006-04-01), pages 942 - 951 *
TUNCMAN G. ET AL.: "Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance", PROC. NATL. ACAD. SCI. USA, vol. 103, no. 28, July 2006 (2006-07-01), pages 10741 - 10746 *
USUI I. ET AL.: "Cdc-42 Is a Rho GTPase Family Member That Can Mediate Insulin Signaling to Glucose Transport in 3T3-L1 Adipocytes", J. BIOL. CHEM., vol. 278, no. 16, April 2003 (2003-04-01), pages 13765 - 13774 *

Also Published As

Publication number Publication date
WO2008016995A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
SI1733707T1 (en) Infusion Cannula System
EP2120959A4 (en) Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
GB0619860D0 (en) Treatment of insulin resistance and disorders associated therewith
WO2008000512A3 (en) Method for identifying crmp modulators
EP2000164A4 (en) Self-destroying disposable syringe and self-destroying method thereof
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
EP2081621A4 (en) Puncturable membrane for safety syringe
WO2008008495A3 (en) Stereocomplex-forming composition and implantable medical device comprising same
EP1889618A4 (en) Combined drug for treating diabetes
WO2007121147A3 (en) Disheveled pdz modulators
WO2010007175A3 (en) Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them
EP2056904A4 (en) Syringe, capsule device therefore, and syringe device
GB2441430B (en) Safety hypodermic syringe
WO2008016995A3 (en) Methods of identifying modulators of insulin signalling
WO2011017488A3 (en) Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity
GB2445733B (en) Medical syringe
GB2437919B (en) Safety syringe
TWM300112U (en) Safety hypodermic syringe
EP2049176A4 (en) Improved safety syringe
WO2008008507A3 (en) Methods of treatment of diabetes
AU2006906937A0 (en) Treatment of Diabetes
AU2005904634A0 (en) Safety needle for syringe
AU2006900314A0 (en) Syringe back-lock clip
HU0400847D0 (en) Pharmaceutical composition for the treatment of diabetes
AU2005901232A0 (en) Safety syringe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07840640

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07840640

Country of ref document: EP

Kind code of ref document: A2